Company Overview
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
Why Investors Should Care
Revenue has grown at a 104.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $32.04M (+104.8% YoY); net profit $-46.50M.
- Trailing 12 Months Year-on-year growth — revenue +102.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 104.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 104.81% |
| 1 Year: | 102.40% |
Stock Price Performance
| 1 Year: | -5.62% |
| 6 Months: | - |
| 3 Months: | -12.68% |
| 1 Month: | -9.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)46.13 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 104.8% over 5 years.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MOBI Mobia Medical, Inc. PHARMA | 11.09 | -5.75 | $369.20M | 0.00% | -75.08% | - | 104.81% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 5.66M | 12.07M |
| Gross Profit | 4.65M | 9.94M |
| Operating Income | -10.30M | -16.94M |
| Net Income | -10.65M | -17.74M |
| Diluted EPS | -12.97 | -19.30 |
| R&D Expense | 1.35M | 1.69M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 15.64M | 32.04M |
| Cost of Revenue | 3.19M | 6.07M |
| Gross Profit | 12.45M | 25.98M |
| Operating Expenses | 36.69M | 72.34M |
| Operating Income | -24.24M | -46.37M |
| EBITDA | -23.50M | -45.37M |
| Interest Expense | 969.92K | 967.37K |
| Pretax Income | -24.59M | -46.49M |
| Tax Provision | 13.91K | 5.45K |
| Net Income | -24.60M | -46.50M |
| Diluted EPS | -1.08 | -0.02 |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -24.32M | -45.69M |
| Investing Cash Flow | -40.85K | -364.41K |
| Financing Cash Flow | 15.66M | 65.03M |
| Capital Expenditure | -40.85K | -364.41K |
| Free Cash Flow | -24.36M | -46.06M |
| Net Change in Cash | -8.70M | 18.97M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | 79.6% | 81.1% |
| Operating Margin % | -154.9% | -144.7% |
| Net Margin % | -157.3% | -145.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | SR One Capital Management, LP | 5.97% | 1.99M | $20.93M |
| 2 | Farallon Capital Management LLC | 3.39% | 1.13M | $11.89M |
| 3 | Avidity Partners Management, LP | 2.40% | 798.28K | $8.41M |
| 4 | Deerfield Management Company, L.P | 2.01% | 670.75K | $7.07M |
| 5 | Aberdeen Group plc | 1.76% | 584.57K | $6.16M |
| 6 | Perceptive Advisors Llc | 1.57% | 523.65K | $5.52M |
| 7 | Vanguard Capital Management LLC | 1.33% | 444.36K | $4.68M |
| 8 | Rock Springs Capital Management, LP | 1.26% | 418.20K | $4.41M |
| 9 | Balyasny Asset Management LP | 1.16% | 387.50K | $4.08M |
| 10 | Integral Health Asset Management, LLC | 0.75% | 250.00K | $2.63M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MOBI
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1kYldzbWV4VjRYYmIzcU5iSk9mRkJSUmdBVjhXYUZienllekNRT0VhR1Jxb2FzUlRwSEVjREpJZlRHemZKcHlldDZXX01SQU5B?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Mobia Medical, Inc. Common Stock (NASDAQ: MOBI) Share Price, MOBI Stock News, MOBI Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE5kemhwSUF2UV9OUTBsQ0NJUHVvQWlQa0YyQWU5N19vNlFsRDVsTzljdWhrSlZ4dHVfTVJ5R29uVnRaT0dZMkZJaDhuQm5WMm5vdmxOZE9B?oc=5" target="_blank">Mobia Medical, Inc. Common Stock (NASDAQ: MOBI) Sha…
Latham & Watkins Represents Mobia Medical in US$150 Million IPO - Latham & Watkins LLP
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTFBWT2M0dVFQak04SDlCNTRNYWZkQXI4aWdUT2kzTER4M3hWVW81dGhabk9HVkRuUHo2Y1Bad0Njay1FT2tWRklfY0I3RzRwc1JrMzM0Z3JranVsMEV1WGNHRlFzM3pKeXRfcTVoTjBGa0gxYzhYemhIMW1ZalZyZw?oc=5" target="_blan…
Mobia Medical (MOBI) Stock Price, News & Analysis - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE1tcVBCTVJWM3lWTkhuQTJmVUw3NC1IYkc1OENxekpkeER0aVJrU2ozNHhDM25VOGI5TUd5WjJhT3B4QzRzTkM5MW0wT1pIQjVTbXo0?oc=5" target="_blank">Mobia Medical (MOBI) Stock Price, News & Analysis</a>&n…
Mobia Medical (MOBI) Stock Forecast and Price Target 2026 - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5wcEFQMUs4b3UyWlZMVlJqTE5DNTRESXFoRlFVdjlET0hmaXNjUnc3M2lGZld3UGM1OUJzc2trdlh1aXFaNnJmajVwTllsZk9MeTJySkFocFphS2RNQkRiUUJKLTdGdw?oc=5" target="_blank">Mobia Medical (MOBI) Stock Fo…
Mobia Medical: A Tough Debut For This Stroke Medical Business (NASDAQ:MOBI) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPbDRhTnV2M3l5Nkt2NGdwOFNOYWNGX0c3eHlZTjNwVDNaeUtLOHd0NzJjN2ZDZG5ZLXhKeXlSUHBpaTNvcGdFRkpITHl4OFFzeGhIUGhYaFFoX0tQVFdYWi1LeDF5SWlDV1JFWmhicC1tUGVLRGVNVFdPeFpIVmJwTUVJdTU1bEtaRlZwME…
MOBI — Frequently Asked Questions
What is the current share price of Mobia Medical, Inc. (MOBI)?
As of 2026-09-19 21:16 PDT, Mobia Medical, Inc. (MOBI) trades at $11.09 on NasdaqGS. Its 52-week range is $10.43 to $14.63.
What is the market capitalisation of MOBI?
Mobia Medical, Inc. (MOBI) has a market capitalisation of $369.20M on NasdaqGS.
What is the P/E ratio of MOBI?
MOBI trades at a trailing price-to-earnings (P/E) ratio of -5.75. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.03.
Is MOBI a good stock to buy?
This page provides a data-driven analysis of Mobia Medical, Inc. (MOBI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.